Novo Nordisk shares fell about 8% after its 2030 strategy—launching five new drugs, targeting oral GLP‑1 growth and 60 million patients—failed to calm investor doubts.
Novo Nordisk’s stock closed lower on Monday, dropping roughly 8% (NVO ‑7.96%, NOVO.B ‑7.65%) after an investor event where the company presented its 2030 ambitions. The decline reflected investors’ lack of reassurance about the firm’s strategic direction.
At the capital‑markets day the Danish drugmaker outlined plans to launch at least five multi‑blockbuster drugs, achieve compound annual revenue growth in line with industry peers, increase focus on oral GLP‑1 medicines and serve 60 million patients worldwide.
The article notes that doubts about the strategy persisted, but does not provide detailed reasons for the skepticism or forecast how the outlined goals will impact Novo Nordisk’s future performance.